Increased expression of matrix metalloproteinases in the murine zymosan-induced multiple organ dysfunction syndrome

Journal of Pathology

Volumn 203, Issue 4, 2004, Pages 968-975

  Volman, T J H ^a   Goris, R J A ^a   Lomme, R M L M ^a   DeGroot, J ^b   Verhofstad, Albert A J ^a   Hendriks, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Gelatinase; Immunohistochemistry; Matrix metalloproteinases; Mice; mRNA; Multiple organ dysfunction syndrome; Zymography; Zymosan

Indexed keywords

AUTACOID; COLLAGENASE 3; GELATIN; GELATINASE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; MESSENGER RNA; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; LIVER PARENCHYMA; LUNG PARENCHYMA; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RNA EXTRACTION; SPLEEN; UPREGULATION; ZYMOGRAPHY;

ANIMALS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MULTIPLE ORGAN FAILURE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; ZYMOSAN;

EID: 4143053758     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1594     Document Type: Article

References (34)

1. Seely AJ, Christou NV. Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit Care Med 2000; 28: 2193-2200.
2. Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001; 29: S99-S106.
3. Goris RJ, Boekholtz WK, van Bebber IP, Nuytinck JK, Schillings PH. Multiple-organ failure and sepsis without bacteria. An experimental model. Arch Surg 1986; 121: 897-901.
4. Goris RJ. MODS/SIRS: result of an overwhelming inflammatory response? World J Surg 1996; 20: 418-421.
5. Jansen MJ, Hendriks T, Verhofstad AA, Lange W, Geeraedts LMJ, Goris RJ. Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome. Shock 1997; 8: 261-267.
6. Volman TJH, Goris RJ, van der Jagt M, van de Loo FAJ, Hendriks T. Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. Crit Care Med 2002; 30: 1553-1559.
7. Demling R, Lalonde C, Youn YK, Daryani R, Campbell C, Knox J. Lung oxidant changes after zymosan peritonitis: relationship between physiologic and biochemical changes. Am Rev Respir Dis 1992; 146: 1272-1278.
8. Shayevitz JR, Miller C, Johnson KJ, Rodriguez JL. Multiple organ dysfunction syndrome: end organ and systemic inflammatory response in a mouse model of nonseptic origin. Shock 1995; 4: 389-396.
9. Cuzzocrea S, McDonald MC, Mazzon E, et al. Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat. Crit Care Med 2001; 29: 102-111.
10. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-464.
11. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002; 169: 2643-2647.
12. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001; 44: 585-594.
13. George SJ. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Invest Drugs 2000; 9: 993-1007.
14. Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer JM. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154: 346-352.
15. Torii K, Iida K, Miyazaki Y, et al. Higher concentrations of matrix nietalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155: 43-46.
16. Yassen KA, Galley HF, Webster NR. Matrix metalloproteinase-9 concentrations in critically ill patients. Anaesthesia 2001; 56: 729-732.
17. Jansen MJ, Hendriks T, Vogels MT, Van der Meer JW, Goris RJ. Inflammatory cytokines in an experimental model for the multiple organ dysfunction syndrome. Crit Care Med 1996; 24: 1196-1202.
18. Volman TJH, Hendriks T, Verhofstad AA, Kullberg BJ, Goris RJ. Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. Shock 2002; 17: 468-472.
19. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatmase by human macrophages. J Immunol 1996; 157: 4159-4165.
20. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HL, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999; 20: 458-464.
21. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002; 86: 1876-1883.
22. Drijfhout J, Nagel J, Beekman B, TeKoppele J, Bloemhoff W. Solid phase synthesis of peptides containing the fluorescence energy transfer Dabcyl-Edans couple. In Peptides. Chemistry, Structure and Biology, Kaumaya PTP, Hodges RS (eds). Mayflower Sci: London, 1996; 129-131.
23. DeGroot J, Verzijl N, Budde M, Bijlsma JW, Lafeber FP, TeKoppele JM. Accumulation of advanced glycation end products decreases collagen turnover by bovine chondrocytes. Exp Cell Res 2001; 266: 303-310.
24. Marijnissen AC, van Roermund PM, Verzijl N, TeKoppele JM, Bijlsma JW, Lafeber FP. Steady progression of osteoarthritic features in the canine groove model. Osteoarthritis Cartilage 2002; 10: 282-289.
25. Nagase H, Woessner J-FJ. Matrix metalloproteinases. J Biol Chem 1999; 274: 21 491-21 494.
26. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996; 3: 895-904.
27. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960-970.
28. Gearing AJ, Beckett P, Christodoulou M. et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-557.
29. Lanchou J, Corbel M, Tanguy M, et al. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit Care Med 2003; 31: 536-542.
30. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol 1998; 2: 466-471.
31. Shapiro SD, Kobayashi DK, Welgus HG. Identification of TIMP-2 in human alveolar macrophages. Regulation of biosynthesis is opposite to that of metalloproteinases and TIMP-1. J Biol Chem 1992; 267: 13 890-13 894.
32. Pagenstecher A, Stalder AK, Kincaid CL, Volk B, Campbell IL. Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am J Pathol 2000; 157: 197-210.
33. Carney DE, McCann UG, Schiller HJ, et al. Metalloproteinase inhibition prevents acute respiratory distress syndrome. J Surg Res 2001; 99: 245-252.
34. Solorzano CC, Ksontini R, Pruitt JH, et al. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock 1997; 7: 427-431.